Stempoint Capital
Latest statistics and disclosures from Stempoint Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SNDX, ROIV, IMVT, CRNX, MRUS, and represent 38.13% of Stempoint Capital's stock portfolio.
- Added to shares of these 10 stocks: IMCR (+$12M), MRK (+$10M), GSK (+$9.5M), SNDX (+$6.4M), DNLI (+$5.8M), CLDX (+$5.3M), ACLX, TCRX, EWTX, CRBP.
- Started 16 new stock positions in GSK, MRK, NGNE, Perceptive Cap Solutions Cor Cl A, CLDX, IMCR, SLN, TCRX, CRBP, NRIX. EWTX, BDTX, Perspective Therapeutics, SRZN, VIGL, DNLI.
- Reduced shares in these 10 stocks: ROIV (-$17M), INSM (-$12M), LLY (-$12M), CRNX (-$11M), TRML (-$6.3M), ANAB (-$6.1M), KALV, SLNO, SLRN, MLTX.
- Sold out of its positions in SLRN, ACHL, ANAB, ANNX, ATXS, RNA, CRGX, CGON, DNTH, IRON. EFTR, KRYS, KYTX, LLY, MLTX, XBI, SLNO, TARS, TSHA, TRML, UTHR, VERA, AVDL, NAMS.
- Stempoint Capital was a net seller of stock by $-23M.
- Stempoint Capital has $331M in assets under management (AUM), dropping by -4.15%.
- Central Index Key (CIK): 0001952142
Tip: Access up to 7 years of quarterly data
Positions held by Stempoint Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stempoint Capital
Stempoint Capital holds 42 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals (SNDX) | 8.8 | $29M | +28% | 1.4M | 20.53 |
|
| Roivant Sciences SHS (ROIV) | 8.7 | $29M | -36% | 2.7M | 10.57 |
|
| Immunovant (IMVT) | 8.1 | $27M | +15% | 1.0M | 26.40 |
|
| Crinetics Pharmaceuticals In (CRNX) | 7.5 | $25M | -30% | 551k | 44.79 |
|
| Merus N V (MRUS) | 5.2 | $17M | -9% | 289k | 59.17 |
|
| Arcellx Common Stock (ACLX) | 4.7 | $16M | +47% | 281k | 55.19 |
|
| Amicus Therapeutics (FOLD) | 4.5 | $15M | -23% | 1.5M | 9.92 |
|
| Immunocore Hldgs Ads (IMCR) | 3.5 | $12M | NEW | 339k | 33.89 |
|
| Applied Therapeutics (APLT) | 3.1 | $10M | +9% | 2.2M | 4.67 |
|
| Merck & Co (MRK) | 3.1 | $10M | NEW | 82k | 124.57 |
|
| GSK Sponsored Adr (GSK) | 2.9 | $9.5M | NEW | 246k | 38.50 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 2.8 | $9.3M | -17% | 2.7M | 3.48 |
|
| Cabaletta Bio (CABA) | 2.7 | $8.8M | -21% | 1.2M | 7.48 |
|
| Kalvista Pharmaceuticals (KALV) | 2.6 | $8.7M | -36% | 737k | 11.78 |
|
| Biohaven (BHVN) | 2.4 | $8.1M | +105% | 233k | 34.71 |
|
| Immatics SHS (IMTX) | 1.8 | $5.8M | +2% | 502k | 11.62 |
|
| Denali Therapeutics (DNLI) | 1.8 | $5.8M | NEW | 251k | 23.22 |
|
| Insmed Com Par $.01 (INSM) | 1.8 | $5.8M | -68% | 87k | 67.00 |
|
| Celldex Therapeutics Com New (CLDX) | 1.6 | $5.3M | NEW | 145k | 37.01 |
|
| Larimar Therapeutics (LRMR) | 1.5 | $5.1M | -4% | 704k | 7.25 |
|
| Tscan Therapeutics (TCRX) | 1.5 | $4.9M | NEW | 845k | 5.85 |
|
| Edgewise Therapeutics (EWTX) | 1.5 | $4.9M | NEW | 271k | 18.01 |
|
| Vistagen Therapeutics Ord (VTGN) | 1.4 | $4.7M | 1.8M | 2.53 |
|
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.4 | $4.6M | NEW | 102k | 45.25 |
|
| Fulcrum Therapeutics (FULC) | 1.3 | $4.3M | +71% | 697k | 6.20 |
|
| Nurix Therapeutics (NRIX) | 1.3 | $4.2M | NEW | 203k | 20.87 |
|
| Pyxis Oncology Common Stock (PYXS) | 1.2 | $4.0M | -32% | 1.2M | 3.31 |
|
| Janux Therapeutics (JANX) | 1.2 | $3.9M | -23% | 93k | 41.89 |
|
| Ideaya Biosciences (IDYA) | 1.1 | $3.6M | +16% | 102k | 35.11 |
|
| Spyre Therapeutics Com New (SYRE) | 1.1 | $3.5M | +141% | 151k | 23.51 |
|
| Perspective Therapeutics Com New | 1.0 | $3.4M | NEW | 344k | 9.97 |
|
| Jasper Therapeutics Com New (JSPR) | 1.0 | $3.3M | +11% | 144k | 22.70 |
|
| Black Diamond Therapeutics (BDTX) | 0.9 | $3.1M | NEW | 674k | 4.66 |
|
| Vigil Neuroscience (VIGL) | 0.9 | $3.0M | NEW | 744k | 4.00 |
|
| Neurogene (NGNE) | 0.9 | $2.9M | NEW | 79k | 36.39 |
|
| Silence Therapeutics Ads (SLN) | 0.7 | $2.4M | NEW | 125k | 19.00 |
|
| Protara Therapeutics Com Stk (TARA) | 0.6 | $2.0M | +283% | 984k | 2.08 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.6 | $2.0M | 200k | 10.22 |
|
|
| Surrozen Com New (SRZN) | 0.5 | $1.6M | NEW | 144k | 10.95 |
|
| Perceptive Cap Solutions Cor Cl A Ord Shs | 0.5 | $1.5M | NEW | 150k | 10.06 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.4 | $1.2M | +8% | 29k | 41.36 |
|
| Arcutis Biotherapeutics Call Option (ARQT) | 0.3 | $1.0M | -51% | 1.5M | 0.70 |
|
Past Filings by Stempoint Capital
SEC 13F filings are viewable for Stempoint Capital going back to 2024
- Stempoint Capital 2024 Q2 restated filed Aug. 13, 2024
- Stempoint Capital 2024 Q1 restated filed Aug. 9, 2024